ABSTRACT The entire chicken genome sequence will be available by the time this review is in press. Chickens will be the first production animal species to enter the "postgenomic era." This fundamental structural genomics achievement allows, for the first time, complete functional genomics approaches for understanding the molecular basis of chicken normo-and pathophysiology. The functional genomics paradigm, which contrasts with classical functional genetic investigations of one gene (or few) in isolation, is the systematic holistic genetic analyses of biological systems in defined contexts. Context-dependent gene interactions are the fundamental mechanics of all life. Functional genomics uses high-throughput largescale experimental methods combined with statistical and computational analyses. Projects with expressed sequence tags in chickens have already allowed the creation of cDNA microarrays for large-scale context-dependant mRNA analysis (transcriptomics). However, proteins are the functional units of almost all biological processes, and protein expression very often bears no correlation to
INTRODUCTION
The term "proteome" was first coined by Marc Wilkins in 1994 at the inaugural two-dimensional (2-D) gel electrophoresis meeting in Sienna, Italy. The proteome was originally defined as the protein compliment of the genome. "Proteomics" was defined as the study of the proteome (Wilkins et al., 1996) . Since then, many definitions have been used. The proteome is context-dependent; it encompasses time, environment, quantity, stoichiometry, and structure including posttranslational modifications (PTM) such as glycosylations and interacting partners. The proteome is diverse and complex and may be infinite (Huber, 2003) . As a discipline, proteomics is immature, using rela-2004 Poultry Science Association, Inc. Received for publication July 29, 2003 . Accepted for publication November 11, 2003. 1 To whom correspondence should be addressed:burgess@cvm. msstate.edu. 552 mRNA expression. Proteomics, a discipline within functional genomics, is the context-defined analysis of complete complements of proteins. Proteomics bridges the "sequence-to-phenotype gap;" it complements structural and other functional genomics approaches. Proteomics requires high capital investment but has ubiquitous biological applications. Although currently the fastest-growing human biomedical discipline, new paradigms may need to be established for production animal proteomics research. The prospective promise and potential pitfalls of using proteomics approaches to improve poultry pathogen control will be specifically highlighted. The first stage of our recently established proteomics program is global protein profiling to identify differentially expressed proteins in the context of the commercially important pathogens. Our trials and tribulations in establishing our proteomics program, as well some of our initial data to understand chicken immune system function, will be discussed. tively immature technologies (Patterson and Aebersold, 2003) and is still rapidly evolving (Pardanani et al., 2002) .
Proteomics will soon become as important to chicken researchers as it has to human researchers. This is because, due to its biomedical utility, the chicken will imminently join those vertebrates that have representative genomes sequenced . For the first time, complete functional genomics approaches, including proteomics, will be completely accessible for understanding the molecular basis of chicken normo-and pathophysiology. The chicken will be the first livestock species to enter the "postgenomic era," and as such the chicken will be a model for other livestock species.
A comprehensive review of every aspect of proteomics is beyond the scope of this paper. Also, this review does not define proteomics simply by the use of mass spectrometry (MS) in biochemistry (although many authors now use the term in that context). With the exception of significant research that impacts proteomics, this review does not include work that is not "omic" in its aims. This review has 2 aims: first, to introduce proteomics and to provide basic information to those who are new to the field and, second, to discuss proteomics specifically in the context of immune responses to infectious pathogens for avian researchers and producers. The exponential growth of proteomics ( Figure  1 ) means it is practically impossible to include every reference for any particular point. Even a recent review of proteomics advances in 2002 alone was unable to be comprehensive in its references (Figeys, 2003) . References are restricted to seminal publications, representative examples, or detailed reviews. This review will deal almost exclusively with understanding wet-laboratory proteomics techniques and technologies and will only briefly discuss critical bioinformatics and computational biology aspects of proteomics.
This review is written from the perspective of someone new to proteomics who wishes to establish the technologies in the laboratory and then to use proteomics as part of an expanding arsenal of tools to understand disease pathogenesis and immunity. Because so much of proteomics is technology driven, and many diverse disciplines have become drawn together into proteomics, it is impossible to discuss proteomics without the use of technical terms and acronyms. A novice to the field can become confused by acronyms. Furthermore "proteomicists" use many of the acronyms as if they were words in their own right. Generally, each acronym is first defined in the text. A list of abbreviations is also provided.
Specifically, this review discusses the proteome and proteomics, describes the contemporary proteomics "toolbox," reviews the "immunoproteomics" literature, and then discusses paradigms for chicken immunoproteomics. An introduction to chicken immunoproteomics at the College of Veterinary Medicine Mississippi State University follows, and the review concludes with some brief personal thoughts.
THE PROTEOME AND PROTEOMICS
A basic literature search (PubMed, NCBI, and NIH) through to the end of 2002 using the search term in the title or abstract: "proteome OR proteomic" demonstrates that proteomics is currently undergoing exponential growth ( Figure 1A ). Even the number of review papers for proteomics published in 2002 averaged 7.9 per week. Four factors are largely fueling growth. First, the complete annotated genome sequences, particularly the human, allow rapid protein identification from MS data. Second, af-FIGURE 1. The exponential growth of proteomics is illustrated by the number refereed publications in PubMed. Total proteomics papers and proteomics reviews (A). Total immunoproteomics papers and immunoproteomics reviews (B). The percentages of proteomics papers that are immunoproteomic are increasing exponentially; this compares with the percentage of genomics papers that are immunogenomic and is static (mean 4.5 ± 0.05) (C). Data derived from literature searches of PubMed, years 1994 to 2002 inclusive; search terms are described in text.
fordable high-throughput technologies now exist to measure proteins from biological samples with excellent sensitivity, accuracy, and rapidity. Third, databases, computer algorithms and modeling have reached the stage at which genomic and proteomic data can be combined to give reliable and biologically meaningful data. Finally, cells and the organisms they make up are protein machines; understanding biology means understanding global protein function. In the majority of instances when it has actu-ally been compared, there is either no correlation or very poor correlation between quantities of mRNA encoding a protein and that protein (reviewed by Goodlet, 2003) . Understanding global protein function requires quantitative measures of protein to be made directly and not inferred or assumed based, for example, on cDNA microarray data.
Although defined above, more detailed examination of what proteome and proteomics currently mean in biology is useful. The proteome is enormously complex. Estimates of the total potential number of proteins produced by the human genome's compliment of ∼40,000 genes are in the vicinity of 500,000 [one human gene alone produces in excess of 1,000 proteins (Ullrich et al., 1995) ]. The human genome contains only about twice as many genes as the fruit-fly, Drosophila melanogaster; the worm, Caenorhabditis elegans; or even plants (Lander et al., 2001; Venter et al., 2001) . This number of genes does not provide the complexity needed for vertebrate growth, maintenance, and function if only a single protein is made from each gene. Complexity is provided by alternate mRNA splicing followed by co-and posttranslational modifications. More than 200 separate protein modifications are documented in vertebrates. More than one of these modifications routinely occurs on most proteins (Gooley and Packer, 1997) .
As implied already, this increased scale of complexity substantially conflicts with the "pregenomic" basic central tenet of "one gene one protein" (Watson and Crick, 1953) . We must await the genome sequence, which has already been shown to be minimized in some areas involving immunity (Reitman et al., 1993; Gobel, 1996; Beck et al., 1999; Kaufman et al., 1999; Su et al., 1999) , to get an estimate of complexity scaling between genome and proteome in the chicken. Nevertheless, the mechanisms behind the increased complexity between the genome and the proteome it encodes are the same in the chicken as in other vertebrates.
Proteomics departs substantially from the reductionism of classical biochemistry in that it is global by nature. By definition, proteomics aims to analyze protein systems in their entirety. In this respect, proteomics commonly operates from a "discovery science" paradigm. Discovery science is designed to identify new avenues of investigation and create new hypotheses rather than being "hypothesis driven." Like other, more established discovery science technologies of genome sequencing and cDNA microarray transcription analyses, proteomics is a fundamental component of a "systems biology" approach. Systems biology may be defined as the systematic and quantitative analyses of all components of a biological system (Aebersold et al., 2000) .
As with many areas in proteomics, opinion varies on exactly what constitutes a "proteomics experiment." At one extreme, the term may be used simply because MS was used as one step toward identifying a protein in what otherwise is classical reductionist biochemistry. At the other extreme, the term proteomics is used only if the experiment surpasses a user's definition of high throughput. From the practical perspective of investigators coming to proteomics from other disciplines, proteomics means investing in new technologies and methodologies, rapidly producing large amounts of data, and then developing new ways of analyzing this data. It is impossible for biologists to do proteomics in isolation from engineers, mathematicians, bioinformaticians, computer scientists, and physicists at least to some degree. The complexity and size of the proteome in a vertebrate has meant that teams of scientists must collaborate in an organized manner. This need lead to the establishment of the Human Proteome Organization (Hanash and Celis, 2002) .
One area of consensus is that proteomics may be divided into 3 broad areas. The first area is termed "expression" proteomics. In expression proteomics, the relative abundances of proteins are measured and compared. Expression proteomics is conceptually equivalent to differential gene expression experiments using cDNA microarrays. The second area is "cellular" proteomics. Here, the aim is to identify protein-protein interactions and to describe the complex interacting networks that are the components of biological machines. The third broad area is "structural" proteomics, in which the goal is to be able to predict the three-dimensional structures of proteins on a genome-wide scale. The basic premise is that if high resolution structures are available for a sufficiently large number of proteins, then all other protein structures could be solved by homology (Chance et al., 2002) . This review will limit itself to the first and second areas because they are most likely to be used initially by investigators outside of specialist facilities investigating specific poultry issues.
Proteomics Toolbox
For proteomics novices it is useful to have an inventory of what is currently in the proteomics "toolbox." Before beginning the inventory however, it is important to note two things. First, the obsolescence rate for proteomics equipment is very fast. Second, unlike genomic sequence data for which the data set may be considered linear and directly obtained, the data set in proteomics is nonlinear and relies on much human intervention and decision making. Correct interpretation of proteomics data requires understanding how proteomics technologies work and understanding their limitations.
There remain many practical problems to be overcome in proteomics. One general problem in proteomics is relatively poor sensitivity. The dynamic range for proteins in tissue is 7 to 8 orders of magnitude, and in serum the dynamic range may be up to 12 orders of magnitude (reviewed by Anderson and Anderson, 1998) . The target-specific exponential amplification afforded by PCR for nucleic acids has no equivalent for proteins. Although work continues toward a protein equivalent for PCR (Fredriksson et al., 2002; Gullberg et al., 2003) , sensitivity issues are generally approached in the wet laboratory by pre-analytical fractionation or at the level of mass spectrometers.
Before beginning to describe the proteomics toolbox, it is important to note that the technologies themselves are well established in other disciplines. It is their integration toward achieving the proteomics goal that defines their utility.
Genomes
Although not absolutely essential, a sequenced genome greatly facilitates proteomics. However, if large amounts of genetic and expressed sequence tag data exist, it is still possible to do proteomics even without a sequenced genome as demonstrated in the chicken by the Beynon group (Hayter et al., 2003) . Simply having a complete genomic sequence is not a panacea; the genome data must be in a useable format. This generally means that at least it can be used for protein identification by matching with MS data. In short, it is best if the genome is well annotated and present in accessible minimally redundant databases [e.g., Swiss-Prot (Bairoch and Apweiler, 1997) and NRDB (National Center for Biotechnology Information)]. This fundamental requirement was immediately recognized for the chicken .
In addition, the genomes of pathogens are of fundamental relevance to the proteomics of immunity and disease. It is axiomatic that well-annotated pathogen genome sequences be available, in addition to the chicken genome sequence, if proteomics approaches are to be applied to deciphering chicken-pathogen interactions.
Bioinformatics and Computational Biology
Bioinformatics and computational biology are critical to proteomics in acquiring, storing, interpreting, and analyzing data as well as building testable models and hypotheses. So that these terms do not appear to be nebulous catchalls, and because bioinformatics and computational biology are so essential to proteomics, they will be defined. The definitions proposed by the US National Institutes of Health (Huerta et al., 2000) are as follows.
Bioinformatics: research, development, or application of computational tools and approaches for expanding the use of biological, medical, behavioral or health data, including those to acquire, store, organize, archive, analyze, or visualize such data.
Computational biology: the development and application of data-analytical and theoretical methods, mathematical modeling, and computational simulation techniques in the study of biological, behavioral, and social systems.
Companies have emerged that offer specific computer solutions for particular proteomics problems. University departments have also invested much effort into developing computing solutions, which are freely available over the World Wide Web. Some of the basic concepts behind bioinformatics and computational biology for specific technologies will be given below when appropriate. In the interest of space and to provide a primer from which readers may then expand their own knowledge, only databases most immediately useful to avian proteomics will be described. Data storage at the investigator's laboratory will then be specifically discussed because of its importance.
Many more or less specialized databases, which are searchable repositories of data for proteomics, exist around the world (reviewed by Various, 2003) . More detailed reviews of databases are available from the reading list in the Appendix. The main nucleotide sequence databases are the EMBL Nucleotide Sequence Database (Europe), GenBank (USA), and the DNA Database of Japan (DDBJ; Japan). These 3 databases are repositories for nucleotide sequence data, and all exchange data daily. Translations of the sequences in these databases, which are then digested in silico, are used to compare with MS data for protein identification. The Swiss-Prot database is the major curated protein database. It is notable for 3 reasons. First, all data is annotated, which means that known features such as PTM, functional domains, and structure and disease associations are included. Second, it is minimally redundant, meaning that it is easier to get all the known data in one search. Third, it is cross-referenced with many other databases containing the 3 types of sequence-related data (nucleic acid sequences, protein sequences, and protein tertiary structures). This means that moving to other databases is a straightforward process. The TrEMBL database is a supplement of Swiss-Prot that contains all translations of EMBL nucleotide sequence entries that are not yet integrated into Swiss-Prot.
The amounts of data generated in proteomics are exponentially larger than that for genomics. As discussed above, the proteome is immensely complex, and there may be large inherent potential variation in proteomics data. Those familiar with cDNA microarrays will be aware that similar issues face transcriptome analyses (Bhanot et al., 2003) . The minimum information about a microarray experiment (MIAME) guidelines that some journals are adopting as a standard before publishing data outline the minimum information requirements for unambiguously interpreting microarray data and to subsequently allow independent verification of this data at a later stage if required (Brazma et al., 2001) . Similar initiatives are just beginning in proteomics.
Two groups are currently addressing the issues of proteomics community standards for data representation to facilitate data comparison, exchange, and verification and to define what is necessary for standard representation of the methods use and data generated in proteomics experiments (Kaiser, 2002; Taylor et al., 2003) . These issues need to be resolved not only for the implementation of proteome repositories but also to optimize protocols in the laboratory and for others to understand an investigator's results. As outlined above, human logic is needed in proteomics; logical interpretation cannot be done without understanding the technologies and knowing the exact settings and protocols.
The terminology for data pertaining to proteomics results is metadata, i.e., "data about data." From the perspective of a biological proteomicist, metadata includes sample preparation methods, liquid chromatography gradients, mass spectrometer settings, and database search algorithm settings. Of course, these examples are data for a mass spectrometrist. Although this may appear intuitive and the sort of thing that would normally be written into the materials and methods section of a publication, the amount of metadata is exponentially greater in proteomics than for most other disciplines. Therefore, metadata is exponentially harder to track in proteomics than in more reductionist biological research. Regardless, keeping, storing, and providing access to proteomics metadata will be a serious issue and is predicted to affect publishing proteomics results in the future.
Electrophoresis-Based Proteomics
Electrophoresis-based proteomics may be done in 1 or 2 dimensions usually using SDS-PAGE, but there are also liquid and gel-based microcapillary systems (capillary electrophoresis and capillary electrochromatography). Regardless, the aim is to deconvolute a complex protein or peptide mixture by taking advantage of the physicochemical properties of the proteins or peptides. The principles are the same no matter what physical appearance the separation system has. This review focuses on PAGE. From a proteomics perspective, one-dimensional SDS PAGE may be useful for subcellular protein complexes or when combined with other technologies [see isotope coded affinity tag (ICAT) below]. Two-dimensional (2-D) PAGE is the electrophoresisbased technology most commonly associated with proteomics (Figures 2 and 6 ). 2-D PAGE was first described in 1974 (MacGillivray and Rickwood, 1974) . But it only became commonly used during the late 1980s and early 1990s when microanalytical techniques, which were able to definitively identify proteins from these gels, became available (reviewed by Rabilloud, 2002) . 2-D PAGE separates proteins in 2 dimensions. The first dimension is separation by isoelectric point (pI) in a polyacrylamide gel, which has a pH gradient, in an electric field (Figure 2, A and B ). This process is called isoelectric focusing (IEF). The pI is the specific pH at which the net charge of the protein is zero. Proteins may be separated by their pI because they are amphoteric (i.e., at a given pH the net charge of a protein is positive, negative, or zero). Proteins are positively charged at pH values below their pI and negatively charged at pH values above their pI. A protein that is positive in the pH range of the gel that it is currently in will migrate toward the cathode and visa versa ( Figure 2B ). Once the protein enters the pH at which it has no net charge, it stops migrating. Notably, changes in PTM (such as phosphorylation) will cause a change in pI without a discernable change in mass detectable in the second dimension ( Figure 2C ).
Originally IEF gels were cast in the investigators' laboratories. Carrier ampholytes, which are small soluble molecules with high buffering capacity near their pI, were used to make the pH gradients. When voltage is applied across the carrier ampholyte mixture in the gel, the carrier ampholytes with the lowest pI (most negative) migrate to the anode and visa versa. However, these gels had a number of disadvantages. Now, IEF gels are available commercially in a plastic backed format ( Figure 2A ) for using the alternative technique of immobilized pH gradients [IPG (Bjellqvist FIGURE 2. Photograph of silver-stained immobilized pH gradient (IPG) strip, from 2-dimensional (2-D) PAGE analysis of neoplastically transformed T lymphocytes from Marek's disease lymphoma (nonlinear pH range 3 to 11, 11 cm; BioRad, www.biorad.com), after soelectric focusing (IEF) and second dimension electrophoresis (A). Many bands can be seen, and these bands are well resolved, demonstrating satisfactory IEF. But protein remains in the IPG strip, demonstrating that not all proteins will migrate into the second dimension SDS-polyacrylamide gel. This occurs in all 2-D PAGE experiments. Schematic representation of IEF (B). Proteins are loaded into the IPG strip, and, because proteins are amphoteric, they carry charges relative to the pH of the environment they are in (i). An electric current is passed through the IPG, and IEF occurs (ii) (i.e., the proteins migrate to the region of the IPG where pH is such that they have zero net charge) (iii). Second dimension SDS PAGE (C). The IPG strip is laid on top of the SDS polyacrylamide gel, again in an electric current. Those proteins that will enter the second dimension will migrate relative to their mass (i), so-called "spot trains" occur when posttranslational modifications (PTM) alter the charge of a subset of the molecules of a given protein but alter the mass undetectably (e.g., phosphorylation) (ii); some proteins will not enter the second dimension (dotted line), whereas those that do, will do so in direct proportion to the amount in the IPG strip (providing the basis of quantification by 2-D PAGE) (iii). PTM are not all or none events; multiple species of a single protein are seen as spot trains (iv). et al., 1982) ]. IPG are created by covalently incorporating a gradient of acidic and basic buffering groups into the polyacrylamide gel at the time it is cast. These IPG IEF gels are less variable and much easier to handle then the homemade IEF gels, resulting in less variation between gels. IEF strips are commercially available in many pH ranges and in linear and nonlinear formats. The second dimension separation is based simply on molecular weight (MW) using an SDS polyacrylamide gel on which the first dimension is laid. Precast linear and nonlinear commercial gels are available to reduce variation.
The most recent manifestation of 2-D PAGE is fluorescence 2-D difference gel electrophoresis [DIGE (Unlu et al., 1997) ]. The advantage of 2-D DIGE is that proteins from 2 different sources may be analyzed and compared in a single gel. This greatly improves experiment accuracy and repeatability. Briefly, proteins are harvested, and total protein is quantified. Equal amounts of proteins from the 2 different sources are then conjugated to 2 different amine reactive dyes. A third dye is used to normalize the gel; a mixture of equal amounts of protein from each source is labeled with this dye. The dyes are designed such that proteins common to both samples have the same relative mobility regardless of the dye used to tag them. Equal amounts of total protein tagged with each of the 3 dyes are then mixed prior to 2-D PAGE. Post-electrophoresis, the gel is imaged into its 3 component images. The images are superimposed, and differences are analyzed by proprietary software.
Regardless of the 2-D PAGE/DIGE method used, sample preparation is critical. In short, the starting material must be solubilized and chemically reduced (to destroy disulphide bonds at cistine residues), and the reduced covalent bonds must be alkylated to prevent disulphide bond reformation. Sample preparation requires a lot of optimization and validation. This optimization and validation must be done using the 2-D PAGE/DIGE system that will finally be used for the actual experiment. It is worth reiterating that sample optimization is fundamental to meaningful 2-D PAGE/ DIGE. Unfortunately, sample optimization is an expensive exercise.
After finally getting to the stage of actually being able to run a 2-D PAGE/DIGE experiment, the experimenter must somehow identify differentially expressed protein spots across the gels. This is not a problem for 2-D DIGE assuming the experimenter has access to proprietary software and specialized equipment. For the more commonly used 2-D PAGE, a number of staining techniques may be used. There is not room here to describe each in detail. In short the 2 most common current methods are Coomassie brilliant blue staining and silver staining. Staining is yet another source of variation in 2D-PAGE, and so protocols must be carefully optimized. Silver has the advantage because it is approximately 50 to 100 times more sensitive than Coomassie brilliant blue staining (silver detects ∼10 3 copies/cell, which is ∼0.01 ng/mm of gel; Coomassie detects ∼10 5 copies/cell, which is 10 ng/mm of gel). However, Coomassie brilliant blue staining is more quantitative than silver staining. Automatic gel stainers are available to help with the issue of consistent staining. Another critical point is that whatever staining protocol is chosen, it must be compatible with MS (although obvious, this point may be overlooked by naive investigators).
The next step is computer-assisted spot differentiation. All commercially available computer programs use the pixels generated by the gel-imaging instrument and software to measure spot size and density. The first thing commercially available programs basically do is to match all of the gels in a particular experiment using some form of land marking. Gel matching is critical because gels distort during fixation and staining; no 2 gels end up the same shape. Next, algorithms normalize each gel in the set using a particular criterion such as background intensity. Finally, after manually establishing sensitivity thresholds, the programs will help operators identify spots expressed differentially in one set of biological conditions but not the other. However, as indicated above, 2-D PAGE is extremely variable. Even experienced and skilled 2-D PAGE "artisans" may get up to 30% variation between gels from the same parent sample run in parallel (S. Vazquez, Waters Life Sciences, Milford, MA, personal communication). Currently in my laboratory we analyze all gels, run in parallel within a biological condition, for variation. We consider good intracondition variation to be 10 to 15%; anything greater and the experiment is rerun from the beginning (i.e., from sample solubilization).
The objective of all proteomics is to have definitive protein identification. To do this for 2-D PAGE/DIGE, protein spots must be cut from the gels, which may be done robotically. The resulting gel plugs are digested with protease while in gel (most commonly using trypsin). The derived peptides are desalted and measured by MS, and the resulting spectra are compared with databases (see below).
The main advantages of 2-D electrophoresis over the electrophoresis-free methods discussed below are that it is an easy method for protein quantification, and it is currently the best method for analyzing PTM. The main drawbacks with 2-D PAGE/DIGE are (1) that the methods require much optimization; (2) the first dimension IEF strips have limited protein capacity, and not all proteins will get into the IEF gel; (3) not all proteins will migrate from the first to the second dimension gel ( Figure 2A) ; (4) the methods are difficult to automate although not impossible (automation is critical given proteomics, by definition, must be high throughput); (5) resolution and sensitivity may be problematic; and (6) 2-D PAGE/DIGE also have relatively poor dynamic range in terms of concentration (10 4 compared with 10 6 for an average cell). Very large, very small, very basic (pI >11), very acidic (pI < 3), and very hydrophobic (e.g., cell membrane) proteins are also problematic.
An interesting recent departure from classical one-dimensional and 2-D PAGE, which has particular merit when used in combination with matrix-assisted laser desorption/ ionization (MALDI) time-of-flight (TOF) TOF MS, is mass spectrometric imaging of IPG gels and creation of virtual 2-D gels (Walker et al., 2001 ). To create these virtual 2-D gels, the IPG strip (after IEF) is loaded directly into a MALDI TOF or MALDI TOF TOF. Not only can a 2-D map be made, but also all proteins that have been loaded into the IPG strip are accessible to mass spectrometric analysis (unlike 2-D PAGE). If a MALDI TOF TOF is used, tandem MS (MSn) fragmentation spectra can be produced directly.
Electrophoresis-Free Proteomics
Because of the restrictions inherent in electrophoresisbased proteomics methods, some proteomicists are devel-oping electrophoresis-free proteomics. Their immediate and easiest aims are to improve on throughput, sensitivity, and dynamic range and the ability to analyze large, small, basic, acidic, and hydrophobic proteins compared with electrophoresis-based methods. Their more difficult aims are to equal, and then improve upon, the ability of electrophoresis-based proteomics methods to quantify proteins and to identify PTM.
Like electrophoresis-based proteomics, most electrophoresis-free proteomics relys on methods of deconvoluting biological samples prior to identification. This deconvolution is primarily based on multidimensional HPLC. A primary initial problem was to determine how to do HPLC at a scale appropriate for samples taken directly ex vivo such that they provided correct concentrations of analytes for MS. To accomplish this, the HPLC columns (containing the stationary phase that initially binds the sample to be analyzed) and the buffer flow rates have been miniaturized to microscales or even nanoscales (Shen et al., 2002) . Commonly in the proteomics literature the words "high performance" are omitted from the acronym, and "LC" is simply used.
The HPLC may be done off line or directly inline with a mass spectrometer fitted with an electrospray ionization (ESI) source (described below). Depending on whether the multidimensional LC is targeted toward entire proteomes or molecular machines, integrated proteomics methods that use multidimensional LC have been called multidimensional protein identification technology [MudPIT (Wolters et al., 2001 )] or direct analysis of large protein complexes (Link et al., 1999) . Reverse phase and strong cation exchange are generally used, although other affinity methods or size exclusion may be used. Many extensive reviews of the technical application of HPLC to proteomics have been written in the last 3 yr, and readers are referred to those for further detail.
MS
Until now this review has discussed tools that deconvolute the proteome. However, mass spectrometers, associated computer algorithms and soft ionization techniques are critical to definitively identify proteins and their PTM and thus for the expansion and evolution of proteomics. Although initially daunting to many classically trained biologists, mass spectrometers are conceptually very simple. Mass spectrometers do one thing with great sensitivity and precision-they measure the masses of very small things. Mass spectrometers have been considered exquisitely sensitive weigh scales that can distinguish between different isotopes of the same compounds. So why is the ability of mass spectrometers to weigh very small things very accurately so critical to proteomics?
Humans define things based on their physical properties. For example, biological molecules may be defined by what they do (e.g., enzymes) or what they bind (e.g., binding a specific monoclonal antibody). For proteins, which are the products of all genes, the primary core structure is amino acids joined by covalent peptide bonds. Any protein of a given weight can only be composed of a finite number and combination of specific amino acids. Of course, the final weight of any protein can be variably decreased or increased by PTM. As a primary protein sequence gets larger (i.e., contains more amino acids) the possibility of it having a unique weight increases. Theoretically all that should need to be done to identify the protein would be to weigh its molecules very accurately. However, the weight of intact proteins almost never definitively identifies that protein. First, a small protein with a lot of PTM may have, by chance, the same weight as a large protein with no PTM. Second, 2 different proteins may contain exactly the same amino acids in the same ratios, although the amino acid sequence is different.
To solve the problem outlined above, 2 techniques are used. The first is peptide mass mapping by endopeptidase digestion ( Figure 3) ; the second is peptide fragmentation, most commonly by collision-induced dissociation (CID; Figures 4 and 5). Endopeptidase digestion is most often done with trypsin, although many enzymes have been used. The concept is that particular endopeptidases cleave peptide bonds in specific places (analogous to restriction enzymes cleaving DNA). Trypsin cleaves on the carboxy terminus of lysine and arginine (unless proline follows, in which case, trypsin will not cleave). For a given protein this produces a specific pattern of cleavage products [i.e., a peptide mass fingerprint (PMF)] of a protein (Figure 3) . The PMF is used to search databases containing translations of all open reading frames in the search set. This may be the genome of a single species, or all sequences of a related group of species, or all DNA sequences in EMBL/Genbank/DDBJ. The translated open reading frames are then digested in silico with the enzyme used in the laboratory to produce a database of all potential in silico PMF. The possibility remains of different peptides having the same amino acids in a different sequence and, therefore, the same mass. But the possibility of this occurring across the entire protein is extremely low. Unfortunately, because of the physicochemistry of soft ionization, PMF peptide coverage of any protein is nowhere near 100%. Often, instead of a definitive match from the database, 2 or more possibilities may exist.
To solve the problem of differentiating between peptides with the same mass but different sequences, molecules of the peptide of interest are physically chosen by the mass spectrometer for fragmentation analysis. When fragmentation is done by CID it may be called MS n (n = the number of generations of fragment ions analyzed). so on). MS 2 is most commonly done and will be described in detail. MS >2 is becoming more common with the introduction of de novo sequencing algorithms. In MS 2 the peptide molecules enter a collision chamber containing an inert gas. As these peptides collide with the gas molecules, they are physically fragmented. Each molecule is fragmented in one place (Figure 4) . The most common but, unfortunately, not the only fragmentation site is the amide bond of the polyamide backbone to produce b ions (the amino acids n-terminal to the fragmentation) and y ions (the amino acids c-terminal to the fragmentation). The masses of all of the pieces of all of the fragmented molecules are then collected. Among this extremely complicated spectra are the b and y ion series. The first b ion (b1) represents the first amino acid, and it will have a corresponding y ion (y1) and so on (although b1 is often not present) ( Figure  5 ). All corresponding b and y ions add to the parental peptide mass. A few extremely skilled people can solve these complex spectra in a matter of only an hour or so per spectrum. Writing from personal experience, I can attest that the rest of us can now very gratefully rely on computer algorithms (Yates et al., 1995; Perkins et al., 1999; Gras and Muller, 2001 ) to solve CID spectra.
Having briefly summarized MS concepts for proteomics, it is now time to describe the machines. A detailed technical description of each type of mass spectrometer will not be given; it is only necessary for proteomicists to have an understanding of which types of machine do what and the limitations of each. To reiterate, MS data must be interpreted. The data appears to be similar regardless of how it is obtained. However, the absolute minimum critical metadata set is the mass spectrometer's sensitivity; its mass accuracy; its resolution, whether you are dealing with monoisotopic masses or average masses; and which PTM (especially those imparted by the chemistry used in sample preparation) are taken into account by the computer algorithm. Investigators have to invest time to learn how to analyze their data. Relying on a final gene "hit," as an investigator might be tempted to do with DNA sequence data, is extremely risky. The investigator must start from the mass spectra. Detailed texts to help with data interpretation are necessary and widely available There are 3 basic components to all mass spectrometers: an ion source that ionizes the molecules of interest, a mass analyzer that differentiates the ions according to their massto-charge ratio, and a detector that measures the ion beam current. Each of these elements exists in many forms, and many combinations have been and are being used to produce a wide variety of mass spectrometers with specialized characteristics. Only the ionization source and the mass analyzers will be reviewed.
Two ionization sources are primarily used, MALDI and ESI for which K. Tanaka and J. B. Fenn shared the 2002 Nobel Prize in chemistry, respectively. In MALDI, either intact protein or a peptide digest is first cocrystallized onto a metal plate with a large molar excess of a matrix compound. This matrix is an ultraviolet-absorbing weak organic acid (e.g., sinapinic acid or a-cyano-4-hydroxycinnamic acid for proteins or peptides, respectively). Ultraviolet laser radiation of this analyte-matrix mixture results in the formation of a plasma and then vaporization of the matrix, which carries the analyte with it into the vapor phase. The matrix is a proton donor and receptor, and it ionizes the analyte. The main advantages of MALDI MS are high sensitivity and high throughput when automated and the ability to archive samples on the MALDI plate for re-analysis at a later time.
In contrast to MALDI, ESI generates ions directly from solution. In the presence of a strong electric field, a fine spray of highly charged droplets is produced. As the droplet decreases in size, the electric charge density on its surface increases. The mutual repulsion between like charges on this surface becomes so great that it exceeds the forces of surface tension, and ions begin to leave the droplet through a "Taylor cone." These ions are electrostatically directed into the mass analyzer. Because ions are formed in solution by ESI, inline liquid chromatography MS is now routine. The ions next travel into the mass analyzer. The mass analyzer is used to separate ions within a selected range of mass-to-charge ratios.
Quadrupole ion traps are the first major class of mass analyzers, often simply abbreviated as "Q." The quadrupole mass analyzers have 4 precisely parallel rods with a direct current voltage and a superimposed radio-frequency potential. Scanning one preselected radio-frequency field effectively scans one mass range. Because they tolerate relatively poor vacuums, quadrupoles are suited to ESI in which the ions are produced under atmospheric pressure conditions. In quadrupole ion traps, ions are trapped in a radio-frequency quadrupole field. The ions are then ejected and detected as the radio-frequency field is scanned. One ion species may be isolated by ejecting all others from the trap. The isolated ion species can then be subjected to CID.
The second class of mass analyzers includes the TOF analyzers that are commonly used with MALDI. The TOF analysis is based on accelerating a set of ions through a flight tube to a detector with a standard force. All ions have the same energy but a different mass so the ions reach the detector at different times. The smaller ions reach the detector first because of their greater velocity; larger ions take proportionately longer. Therefore, the analyzer is called "time-of-flight," and mass is determined by the ions' time of arrival. MALDI TOF machines fragment peptides by postsource decay directly on the MALDI target after the laser power is significantly increased. However, postsource decay does not provide the quality of fragmentation data provided by CID, and up to 10 separate spectra of different mass regions may need to be obtained and combined. MALDI TOF TOF machines have 2 flight tubes separated by a fragmentation chamber so fragmentation analysis by CID can be done. The high energy CID in MALDI TOF TOF results in side-chain loss fragment ions, which allow the differentiation of the isomers leucine and isoleucine (Yergey et al., 2002) .
The third class of mass analyzers is the Fourier-transform (FT) ion cyclotron resonance (ICR) mass analyzers. FT-ICR has extremely high resolution, sensitivity, and mass accuracy as well as the ability to do MS n . FT-MS is based on the principle of charged particles orbiting in the presence of a magnetic field. While the ions are orbiting, a radiofrequency signal is used to excite them. As a result of this radio-frequency excitation, the ions produce a detectable image current on the cell in which they are trapped. The time-dependent image current is then Fourier-transformed to obtain the component frequencies of the different ions, which correspond to their mass-to-charge ratios. Until now the cost of FT-ICR machines was prohibitive for all but a few laboratories. However, competitively priced FT-ICR machines will be available after August 2003. These machines are coupled to ion traps that further increase sensitivity.
Like 2-D PAGE/DIGE, certain proteins are problematic for MS analysis alone or in combination with HPLC. Most of the problem is that salts and detergents are incompatible with MALDI and ESI. This incompatibility conflicts with traditional protein isolation protocols. Cell membrane proteins are typically difficult to isolate, and these molecules are of critical importance. However, a great deal of work is ongoing to solve the cell-membrane protein problem. This work is targeted at global expression analysis (Wu et al., 2003) and at identifying specific proteins (Arnott et al., 2002) . The latter is suggested to be a replacement for Western blotting of proteins, and for this reason the phrase mass Western analysis was coined.
Other and Emerging Technologies
So far the most common proteomics technologies used by established proteomics laboratories have been reviewed. It is worthwhile to briefly alert readers to other technologies used for proteomics research and also emerging technologies that will become important to the chicken community. Generally when technologies that already exist are applied to proteomics, they are scaled up and are done in high throughput. An archetypal example is the large-scale yeast 2-hybrid screen in the yeast Saccharomyces cerevisiae, which resulted in the detection of 957 putative interactions that involved 1,004 proteins (Uetz et al., 2000) . In more direct "guilt-by-association" approaches, large-scale coprecipitation technologies may be used. Two models for this approach, again done in S. cerevisiae, are coprecipitation after large-scale Flag epitope tagging (Ho et al., 2002) and tandem affinity purification tagging (Gavin et al., 2002) . Tandem affinity purification tagging has been used on a smaller scale to analyze multiprotein complexes (Tasto et al., 2001) as have antibodies (Sanders et al., 2002) .
Three emerging proteomics technologies are quantitative methods for electrophoresis-free proteomics, protein/peptide arrays, and imaging MS. Quantitative methods for electrophoresis-free proteomics rely on the sensitive ability to distinguish small differences in mass. The general principal underlying all of these quantitative MS methods is to label, either in vitro or in vivo, the proteins from cells under one set of conditions with heavy isotopes and those from another set of conditions with light isotopes. One example is ICAT (Gygi et al., 1999) . In ICAT experiments, equal masses of total protein from the 2 conditions to be compared are labeled with a heavy or a light tag. These proteins are then digested with a protease, and the tagged peptides are isolated using affinity columns. When analyzed by ESI MS, the same peptides from each sample are equally ionized. Thus their relative concentration can be directly compared. The defined difference in mass allows identification of each peptide in the mass spectra.
Arrays are now being developed in which thousands of proteins, peptides, or antibodies are spotted as microarrays on glass or plastic slides. Analogous to cDNA microarrays, protein arrays (1) profile the relative abundance of proteins in complex mixtures (protein expression profiling), (2) detect interactions (antibody-protein, protein-protein, protein-DNA, protein-small molecule), and (3) determine protein activities. Bound proteins are detected by adding antibodies tagged with fluorescent molecules or by chemically labeling all the proteins in the sample before analysis. The signal intensity represents the amount of bound protein. Protein expression arrays, like their genetic counterparts, generate signatures for different cell types and tissues. For functional arrays, different proteins are analyzed for the molecules they bind. The proteins in question, rather than the antibodies recognizing them, are arrayed on a slide. Protein binding information can also be obtained by using a small molecule microarray, in which thousands of different small synthetic molecules are arrayed on the slide. These small molecule arrays are primarily drug discovery tools but can also be used as research tools to define novel reagents that interfere with the function of a protein.
Imaging MS is a technique that uses MS directly to image tissue sections (Stoeckli et al., 1999; Chaurand and Caprioli, 2002) . Tissue sections, cut as for any histological analysis, are analyzed directly using a MALDI TOF mass spectrometer. Imaging MS is the MS equivalent of immunohistochemistry except that global protein profiles are produced. Although in its infancy, imaging MS has been used for mapping and imaging of biomolecules and drugs directly from tissue sections and produces mass spectral signatures for tissues in health and disease.
Immunoproteomics
Like everything else in the "omic" world, proteomics when applied to immunology and immunity has acquired its own term, "immunoproteomics" (Jungblut, 2001 ). This term, however, is recent and is not adequate on its own to identify the literature concerning the proteomics of immunology and immunity in literature searches. A literature search (PubMed) for publications up until the end of 2002 used the search specific term in the title or abstract [(proteome OR proteomic) AND (immune OR immunology OR immunity OR vaccine OR leukocyte OR lymphocyte OR cytokine) NOT plant)]. From this search it is clear that there was a lag time of just 1 yr from the time of first publication of the term proteome (Wasinger et al., 1995) to its first publication in connection with immunology (Qi et al., 1996) ( Figure 1B ). For both proteomics generally and immunoproteomics specifically, approximately one-quarter of published papers are reviews (mean/year = 26.6 and 24.0 %, respectively). Like proteomics in general, an exponential model best fits the increase in immunoproteomics publications. Finally, immunoproteomics and immunogenomics/ transcriptomics {search term in title or abstract: [(cDNA OR microarray OR transcriptome OR transcriptomic OR genomic) AND (immune OR immunology OR immunity OR vaccine OR leukocyte OR lymphocyte OR cytokine) NOT plant)]}, on average, compose ∼4% of the total proteomics and genomics/transcriptomics literature. However, compared with immunogenomics/transcriptomics, which has stablized at about 4%, immunoproteomics publications are increasing exponentially ( Figure 1C ). All the indications are that proteomics will significantly impact immunobiology.
Immunoproteomics is in its infancy. Many proteomics tools that to date have not been published in an immunoproteomics context undoubtedly soon will be. As of June 2003, there were only 85 primarily immunoproteomics research publications (using the above criteria) out of 1, 485, 197 Proteomics relies on a set of platform technologies and has wide-ranging applications in many disciplines. In general, however, proteomics provides at least one of the following:
1. Definition of genomes by distinguishing putative open reading frames that actually encode proteins from those that do not and by identifying protein species that cannot be predicted from the structure of the genome or transcriptome alone. 2. Maps of protein expression and differential protein expression to obtain signatures in, and for, specific contexts and to establish comparative databases. 3. Definition of molecular machines, interacting protein complexes, and so on up to the much larger scale of quantitative modeling global interacting protein networks. 4. Predictions of molecular structure, utility, or function based on experimentally defined knowledge primarily using bioinformatic modeling. The paradigm for this review is that proteomics is valuable for defining disease pathogenesis and immunity; proteomics will provide insights into and suggest novel hypotheses for improving health. The immunoproteomics literature can arbitrarily be separated into general groups that (1) define immune system function and dysfunction from primary structure, to higher order structure, to a global level; (2) define pathogens from primary structure, to higher order structure, to a global functional molecular level; (3) identify immunogens and epitopes particularly in the context of the genetic basis of host disease resistance and susceptibility and also identify virulence and attenuation determinants of pathogens and related vaccine strains; and (4) define the molecular machines used in host immunity and pathogen immune evasion. Although there is some intersection, most immunoproteomics publications predominantly describe mapping and databases; the next most common immunoproteomics publications predominantly describe the functions of molecular machines and higher multiprotein complexes. Publications that define the immunogenome and primarily use bioinformatics are least represented. 2-D PAGE and MALDI TOF MS are the most common techniques used to date.
Two papers from the same group, using mouse fetal thymus cDNA libraries, define some of the elastic capacity the genome provides the immune system. Using in vitro translation methods that allow PTM, their approach allowed identification of rare protein species that otherwise would not have been detected by traditional proteomics technologies. Multiple protein species were derived from single RNA. These multiple protein species might have be due to PTM or resulted from programmed degradation. The group concluded "that in most instances expressed genes yield transcript(s) that translate into several, and often very numerous families of polypeptide species." With 2-D PAGE, the proteomic profiles of the clonal polypeptide families were mapped in terms of mass, charge, multiple products, and appearance in 2D PAGE (Lefkovits et al., 2001; Kettman et al., 2002) .
Proteome maps aimed at understanding gene expression in immune system development, physiology, disease, and pharmaco-therapeutics have been established but are not yet comprehensive. Databases for normal human CD19+ B, CD4+ T-helper, and CD8+T-killer lymphocytes were established by Vuadens et al. (2002) . Although the B-lymphocyte proteome segregated from the T-lymphocyte proteome, and the CD8+ T-lymphocyte proteome segregated from CD4+ lymphocyte proteome, no spots were B-lymphocyte specific. The ability of 2-D page to discriminate between cells with known differences is encouraging, but the absence of known B-lymphocyte-specific markers in the discriminatory proteomes (CD19 itself and the rest of the surface immunoglobulin complex) exemplifies one limitation of 2-D PAGE. A proteome database of primary human T-helper cells was established using 2-D PAGE and MALDI (Nyman et al., 2001) . Although ∼1,500 protein spots were detected in the resulting 2-D gels with silver staining, and ∼2,000 spots with autoradiography, only 91 were identified by PMF at the time of publication. Joubert-Caron et al. (2000) used in vitro EBV-immortalized lymphocytes to produce an annotated reference map of human B-lymphoblastoid cell proteins.
Moving more toward function, murine B-lymphocytes activated by lipopolysaccharide have been mapped , as has have murine T lymphocytes activated in the presence of the immunosuppressive drug cyclosporin A (Mascarell et al., 2000) and also reactivating after cyclosporin A removal (Truffa-Bachi et al., 2000) . B lymphocytes were shown to utilize sequential waves of functionally related proteins to anticipate antibody secretion (van Anken et al., 2003) . Proteomics identified caspase activation to be important to the phenomenon of oral tolerance of CD4 T lymphocytes. In addition to caspase-3 expression, the tolerant CD4 T cells unregulated anti-apoptotic factors and could not form normal T-cell receptor signaling complexes (Kaji et al., 2003) . Wang et al. (2002) mapped the effect of a novel potential immunomodulator on splenocytes and identified, among other proteins, upregulation of the cytokines interleukin (IL)-1, IL-2, and interferon (IFN)-γ. Formation of mixed disulfides between glutathione and the cysteines of some proteins (glutathionylation) was suggested to be a mechanism of global regulation of protein functions by redox status using T lymphoblasts that undergo glutathionylation during oxidative stress. Nonreducing 2-D PAGE was used, and labeled proteins were detected by phosphorimaging then identified by MS [redox proteomics (Fratelli et al., 2002) ].
Cytokines play critical roles in immunomodulation, and proteomics has revealed ubiquitin-conjugating enzymes to be regulated by IFN-α. Ubiquitin conjugation is a ratelimiting step in antigen presentation and therefore the upregulation of ubiquitin-conjugating enzymes by IFN may contribute to the enhanced antigen presentation by macrophages (Nyman et al., 2000) . IFN-γ affects fresh human bladder transitional cell carcinoma culture proteomes, but any potential utility for this cytokine in bladder cancer management is still to be defined (Aboagye et al., 1998) .
The innate immune system is important for controlling pathogens immediately after infection or even at the time of pathogen entry. Le profiled changes in transcriptome and proteome during differentiation and maturation of monocyte-derived dendritic cells by both DNA microarrays and proteomics. Novel genes associated with dendritic cell differentiation/maturation and PTM of specific proteins were identified to be part of the differentiation and maturation processes. Notably, there was little concordance between cDNA and proteomics results, showing that to get a complete understanding of how the system works transcriptomics and proteomics were needed. In work targeting the role innate immune cells play in the outcome of disease secondary to pathogen infection, a proteomics signature from macrophages predicted HIV-1 was associated with cognitive impairment (Luo et al., 2003) . Subcellular organelles operate as machines in their own right. At this subcellular level, the molecules by which dendritic cell exosomes modulate their adjuventicity were described by Thery et al. (2001) , and human butyrophilin in milk fat globules were suggested to provide breast-fed infants with immune molecules by Cavaletto et al. (2002) . Lower vertebrates and insects are used as comparative models to identify innate immune molecules and antimicrobial peptides. Protease inhibitors have been mapped from the skin secretions of the crawfish frog, Rana areolata (Ali et al., 2002) .
Not all immune responses and immune and nonimmune cell interactions are beneficial. Immunopathologies are important causes of disease. Proteome mapping has implicated IFN-γ, IL-1, and IL-6 in the pathogenesis of inflammatory bowel disease (Barcelo-Batllori et al., 2002) and IFN-γ in human skin aging (Gromov et al., 2003) . The deleterious effects of IL-1β on islets of Langerhans in a rat model of diabetes were mapped at a proteomic level, including identifying changes in PTM (Larsen et al., 2001) . During work aimed at identifying the mechanisms underlying cancer metastasis, a potential role for IL-18 was suggested (Jiang et al., 2003) . IL-18 was present in a highly metastatic cell line but absent in a poorly metastatic cell line. Both cell lines were derived from the same parental cell line. The association of IL-18 with metastasis was supported by IL-18 sense/IL-18 antisense experiments.
Another form of proteomics mapping, but one specific to immunoproteomics, is identification of target antigens in natural immune responses for rational vaccine design (Nilsson, 2002) . For antibodies, mapping is done by Western blotting 2-D polyacrylamide gels with immune sera and has been called serological proteome analysis (Eschenbrenner et al., 2002) . The antigens are identified either after protease digestion of spots cut from nonimmunoblotted matched gels or by protease digestion of spots cut directly from the nitrocellulose/polyvinylidene difluoride membrane. Identifying antigens recognized by CD8+ T-killer lymphocytes and CD4+ T-helper lymphocytes by MS was pioneered by Hunt et al. (1992a,b) in the preproteomics era. The peptides recognized by CD8+ and CD4+ T lymphocytes bind to MHC classes I and II, respectively. The concept behind identifying T-lymphocyte antigens is to purify MHC class I or II through immunoaffinity assays and then to elute the bound peptides. The peptides are then identified by MS n . Since the sequencing of pathogen genomes, antigen mapping has become more accessible. Proteomic B-and T-lymphocyte antigen mapping has been used to identify immunogens in allergy (Ou et al., 2001; Beyer et al., 2002; Yu et al., 2003) , autoimmunity (Ochi et al., 2002; Robinson et al., 2002; Thebault et al., 2002; Bohring and Krause, 2003; Orru et al., 2003; Stulik et al., 2003) , cancer (Prasannan et al., 2000; Knezevic et al., 2001; Murphy et al., 2001; Paweletz et al., 2001; Sreekumar et al., 2001; Vercoutter-Edouart et al., 2001; Benvenuti et al., 2002; Brown and Nazmi, 2002; Celis et al., 2002; Rai et al., 2002) , and infectious diseases (Hendrickson et al., 2000; Buranda et al., 2001; Covert et al., 2001; Holtappels et al., 2002; Montigiani et al., 2002; Veith et al., 2002; Cullen et al., 2003; Guina et al., 2003; Yatsuda et al., 2003) In conjunction with a high-throughput version of a classical immune T-lymphocyte function test, proteomics was used to map the T-lymphocyte antigens of Mycobacterium tuberculosis (Covert et al., 2001 ). Subcellular protein fractions of M. tuberculosis were resolved by 2-D liquid phase electrophoresis. These fractions were then tested in lymphocyte stimulation assays using splenocytes from mice previously infected with M. tuberculosis. Thirty individual immunogenic proteins contained in the 2-D liquid phase electrophoresis fractions were identified by liquid chromatography MS and MS n ; many represented previously defined antigens, but 17 were novel T-lymphocyte antigens.
So far only the identification of antigens that are naturally immunogenic (or at least have peptides bound to MHC class I and II) have been discussed. However, this does not address the issue of hidden antigens to which no preexisting immune response may be detected (Thoren et al., 2002; Yatsuda et al., 2003) . The proteome of all pathologies is rich in potential immunogens, and differential proteome mapping has been done for many pathologies, especially cancer. Some examples of cancer proteomics that relate to immunology are identified above. The differential proteome mapping of pathogens will be further discussed. The proteomes of many human and some animal pathogens have been mapped, and many more will be. Not only will pathogen proteome maps confirm (and modify) each genome's annotation, but these proteomes will also differentiate conserved from stage-specific proteomes. They will also define internal, membrane-associated and secreted, proteomes. Each proteome is of potential interest for vaccine design.
The impact of pathogen proteomes will be greater than just identifying potential vaccine antigens. Many of the mechanisms of pathogen virulence and vaccine attenuation are not understood. Nor are such mechanisms detectable at the genetic level because they are hidden in the "noise" of variation that is in (especially the larger) polymorphic pathogen genomes. Differential proteome analysis has identified pathogen virulence and attenuation mechanisms (Ferrari et al., 1999) . Specific mechanisms of pathogen immune evasion have also been described using proteomics.
Group A Streptococcus has a secreted protein with homology to the α-subunit of Mac-1, a leukocyte β2 integrin required for innate immunity, which inhibits opsonophagocytosis and thus evades human innate and acquired immunity (Lei et al., 2001) .
One of the goals of proteomics is to describe the functional protein complexes. Proteomics has been used to define the detergent-resistant membrane skeleton from neutrophil plasma membranes and lipid rafts (Nebl et al., 2002) . Lipid rafts are important for localized signal transduction. Cascades of adaptor protein and kinase recruitment to lipid rafts are critical during receptor activation. In other work, IgM has been shown to be associated with the Sp-α (CD5 antigen-like) molecule. Sp-α is a member of the scavenger receptor cysteine-rich superfamily of proteins, and other members of the superfamily influence immune cell fate. The authors propose a role for Sp-α in IgM homeostasis .
Last, 2 papers exemplify primary bioinformatics approaches to immunoproteomics. Ristori et al. (2000) investigated whether molecular mimicry affects the shaping of the helper T-cell repertoire. They used an algorithm that measures the probability of mimicry between epitopes of known immunogenicity. Self or nonself proteomes were derived from human or microbial data in Swiss-Prot. The authors conclude that "mimicry, rather than complicating self-nonself discrimination, assists in the shaping of the immune repertoire and helps define the defensive or autoreactive potential of a T cell." This model fits with the laboratory data in which an inflammatory environment is needed to break immune tolerance. The authors claim that, being a predictor of epitope immunogenicity, their algorithm is relevant to vaccine design. As part of an iterative research process, this claim is easily testable.
A computational approach was taken in human cancer immunology aimed to understand the correlation between the immunogenicity of peptides derived from tumor-associated antigens relative to the similarity level to the host's proteome (Mittelman et al., 2002) . The authors used the breast and prostate cancer-associated HER-2/neu antigen and computationally defined similarity with the host's proteome. These epitopes were then experimentally tested for reactivity using human polyclonal sera from patients with breast or prostate cancer. Peptide sequences with medium or low similarity to the human proteome were preferentially recognized by breast and prostate cancer patient sera. Perhaps not surprisingly, the authors concluded that "low level of sequence similarity to the host's proteome might be an important factor in shaping the pool of B cell epitopes." The authors claim "new directions for the application of computational biology to anti-cancer vaccine research" and to have provided "experimental strategies applicable to the identification of functionally relevant epitopes within disease-associated-proteins." Although true to some degree, the approach outlined takes no account of IgM or T-cell receptor avidity or affinity to HER2/neu in its natural context, antigen expression levels (important in HER2/neu), the natural availability of CD4+ T lymphocyte help, and assumes only that central, but not peripheral, silver-stained, nonlinear pH range 3 to 11, 11 cm immobilized pH gradient (IPG), linear SDS-PAGE; Criterion, BioRad, www.biorad.com; collaboration with M. Parcells, University of Arkansas]. The gel shown was produced from the IPG strip in Figure 3 . Analysis for differentially expressed spots between two types of Marek's disease lymphoma, caused by different pathotypes of Marek's disease herpesvirus (B). Three replicate 2-D PAGE gels were run for each pathotype. Criteria for differential expression was >2-fold difference for the most similar gels, between groups of gels, from each pathotype. Differentially expressed spots are marked by "X". Graphs show absolute expression as [silver-stain intensity/background intensity immediately adjacent to spot (or corresponding pixels from gels without spots as appropriate)]; units are parts per million (analysis software PDQUEST, BioRad, www.biorad.com) Zoom view of dashed boxes (B) showing spots to be cut out for processing for MS analysis (C). FIGURE 8. MALDI-TOF peptide mass fingerprint analysis of nondifferentially expressed spot cut from the 2-dimensional (2-D) PAGE gel in Figure 7 . The spot was digested in gel by using sequencing-grade modified trypsin (Promega, www.promega.com/default.asp). The MS data (A) is of high resolution as demonstrated by the isotopes of the mono-isotopic peak at 1,243.7760, increasing by almost exactly 1 Da per isotope (inset). Protein identified as (nonmuscle) chicken tropomyosin 1, obtained from database search using the Mascot search engine and database (Perkins et al., 1999) . Matching peptides are underlined in sequence.
tolerance is important when establishing primary immunity or enhancing secondary immunity. It would be interesting to test the authors' model with autoimmune models (the flipside of tumor immunity) and models of molecular mimicry of host epitopes in infectious disease.
Paradigms for Chicken Immunoproteomics
The background information above leads us to a discussion of immunoproteomics in the chicken. To date, with one notable exception from the Beynon group at the Uni- ) analysis of bacterial protein (Haemophilus spp.; collaboration with M. Lawrence, Mississippi State University) after trypsin digestion (as above). Data from pool of different proteins analyzed en mass (ProteomeX LCQ DecaXP, Bioworks analysis software, Thermofinnigan, San Jose, CA). (A) After setting appropriate statistical stringencies, the first protein was identified by the first of its peptides (PGIVIGK) at ∼5.8 min of ion current (arrowed in top panel), at scan 169, as ribosomal protein S3 (rpS3, middle and bottom panels). Overall, rpS3 was identified by 6 peptides above threshold stringency (underlined), i.e., 24.26% coverage (B). The b-y ion series for PGIVIGK is shown (C).
versity of Liverpool Veterinary School, UK (Hayter et al., 2003) , no wet-laboratory proteomics work in the chicken has been published. No chicken immunoproteomics work has been published at all.
Four points are immediately obvious from immunoproteomics in other species when considering immunoproteomics in the chicken. First, sequenced pathogen genomes, in addition to a sequenced chicken genome, are fundamental. Pathogen genome sequencing is relatively well supported by the USDA and will almost certainly continue to be so. The major impediment to chicken proteomics (i.e., not having a chicken genome sequence) will soon be removed . Second, the proteome is massive, and proteomics has ubiquitous applications. Thus, any imaginative list of possibilities for immunoproteomics could never be comprehensive and would be of little practical use in this review. Third, the exponential growth in proteomics provides a wealth of data in other species from which to plan an immunoproteomics strategy for the chicken. Fourth, the evidence from the Human Proteome Organization suggests that strategic alliances between investigators on a large scale will be critical to efficient chicken proteomics. The small and closely knit avian immunology community may provide an excellent nidus for a similar organization.
The initial priority for chicken proteomics is to identify the genes in the genome sequence , i.e., to do the initial annotation. The value of a genome sequence to a research community is limited by how well it is annotated (Stein, 2001) . The human genome project model is to first annotate the genome, using human experts, based on information in the public domain then to take advantage of data mining and automatic annotation that has been developed from the human proteomics initiative (O'Donovan et al., 2001) . Initially, annotation work will rapidly progress because of existing chicken DNA and cDNA sequences as well as expressed sequence tags. Information available from the published literature on already known chicken genes, and from obviously homologous genes from other species, will facilitate initial annotation. After this stage, however, approaches that analyze real proteins will become critical.
Basic proteome maps of cells and tissues in health and disease and as those of pathogens will be fundamental to defining the chicken genome's functional capacity. In the chicken, for which the immunology research community is much smaller than that of the human, it may be logical to combine basic immunoproteome mapping with differential proteome mapping to compare health with disease. The immune system has inherent plasticity. It is the means of sense and defense against infectious microorganisms and parasites; immunity has co-evolved with pathogens. The immune system must be flexible; no single pathogen can totally evade immunity and replicate completely unchecked if the host species is to remain extant. If proteome maps are to help to define the capacity of a genome, then the diverse array of pathogens, which elicit the huge yet often subtle diversity of host immunity, must provide excellent data for a complete immunoproteome.
The chicken is established as an excellent biomedical model for immunology research. From the accidental invention of attenuated vaccines by Pasteur to the first description of graft vs. host reactions, the first definitive association of specific MHC haplotype with resistance and susceptibility to pathogens, the discovery of B cells and interferon, the first successful vaccines against a cancer, and the first prenatal vaccines, immunology is indebted to 2 Arcturus, http://www.arctur.com/. the chicken (Davison, 2003) . The chicken is beginning to prove itself to be uniquely positioned to elucidate critical sequences in vertebrate genomes .
Although an excellent biomedical model, the main objective for chicken immunologists is to improve poultry health, production, and welfare. Although chicken immunologists almost never care about the individual, and certainly would never treat an individual chicken, the aims of chicken immunologists are similar to the human immunologist. Like humans, chickens live in large dense communities, and, like humans, intensive vaccination is critical in the poultry industries to control infectious disease. Vaccination is likely to become even more important as the political pressure to remove in-feed antibiotic growth promoters increases. Unfortunately, although poultry vaccines to viruses, bacteria, and even parasites are extremely successful, they also select pathogens to evade the immunity induced by these vaccines, thereby increasing pathogen virulence. In addition, the chicken industries are afflicted with ubiquitous immunosuppressive viruses (e.g., chicken anemia virus, infectious bursal disease virus, Marek's disease virus, avian reovirus, and a cluster of retroviruses). Immunoproteomics offers a means of directly identifying novel vaccine immunogens and potential immunogens as well as understanding disease pathogenesis.
Not all chickens are hatched immunologically equal. Immunogenetics is extremely important to chicken production. There are extreme differences in the abilities of chicken genotypes to mount immune responses to both pathogens and vaccines. Furthermore, chickens do different things. Tens of billions of broiler chickens annually worldwide are killed at approximately 6 wk of age for meat. Only hundreds of elite broiler breeders provide the genetics for these broilers. Hundreds of millions of chickens are laying table eggs worldwide at any time (USDA, National Agricultural Statistics Service). The broiler and egg industries are dealing with completely different genotypes. The most obvious differences between broiler and layer chickens is in stature and shape. The chickens in each industry live to different ages under different conditions, eat different food, and suffer from different diseases. The ancestor breed of all domestic chickens, the Red Jungle Fowl, will have its genome sequenced first. One-fold genome sequences of representative broiler and layer genomes are proposed . However, broiler and layer chickens have been intensively selected to survive in different pathogen environments. Their immunogenetics are different; their immunoproteomes are probably even more different. The existence of inbred chicken lines may simplify proteomics analyses as it has genomic analyses.
Chicken Immunoproteomics at Mississippi State University College of Veterinary Medicine
A unique situation allowed me to begin to develop our avian immunoproteomics program at Mississippi State University (MSU) College of Veterinary Medicine (CVM) in January 2002. MSU invested heavily in biotechnology with a particular emphasis on proteomics. In 2001, the MSU Life Sciences and Biotechnology Institute (LSBI) was established and funded to be a core facility with proteomics equipment, training, and seed funding. The Mississippi Functional Genomics Network was established and funded by the National Institutes of Health (NIH). The State of Mississippi is heavily reliant on agriculture for its income, and the poultry industry is the primary income earner. MSU strongly supports Mississippi's agriculture industries, and one of the missions of the CVM is to develop an internationally recognized poultry research program. At the same time, rumors of NIH funding the sequencing of the chicken genome were circulating. My personal background was in genetic resistance to poultry disease. Proteomics in the chicken was a natural fit.
When starting with an empty laboratory, the biggest hurdle to entering proteomics is money. The MSU investment to establish the LSBI has helped greatly. The next most significant problem is finding proteomicists. Such people are a new breed and certainly do not exist for animal research. We are training ourselves. This has its advantages in that we can try to emulate the best, and we can do whatever we want with the equipment. However, the learning curves are extremely steep. The first stage of the proteomics arm of my research program was to decide on technologies. We are taking both electrophoretic and nonelectrophoretic approaches, using both MALDI-TOF and microcapillary liquid chromatography ESI MS n . There is a very large amount of competition in the rapidly developing proteomics marketplace, which can lead to a lot of confusion regarding technologies and instrumentation.
Sample preparation is the single most critical issue in proteomics. We first optimized sample preparation, which sounds straightforward, but the only way to optimize sample preparation is to use the proteomics equipment, which also needs to be optimized at the same time. Because our paradigm is to work directly ex vivo when possible, which means using less tissue than most proteomics experimenters use, we next scaled down. Also tissues are heterogeneous in vivo; to enable us to analyze pure proteomes directly ex vivo, CVM purchased a laser capture microdissection microscope 2 , (Figure 6 , representative example of laser capture microdissected tissue). Since starting our wetlab experiments in May of 2002, we have optimized sample preparation, 2-D PAGE using MS-compatible silver ( Figure  7 ) and Coomassie brilliant blue stains, MALDI-TOF PMF (Figure 8) , and liquid chromatrography ESI MS n ( Figure  9 ). We have optimized methods for various chicken cells and tissues and bacteria including methods for analyzing membrane proteins (data not shown; collaborations with B. Gao, M. Lawrence, MSU; and G. T. Pharr, MSU). We have had to learn a great deal about computer programs for interpreting our 2-D PAGE data (Figure 7 ), how to set up a MALDI-TOF, offline and inline 2-D microcapillary chromatrography systems, and how to interpret both raw MS spectra. We are now beginning our real experiments.
Conclusions
Proteomics is exciting. I was extremely fortunate to be selected as a student at the inaugural Proteomics course at Cold Spring Harbor Laboratories (CSHL) in November 2002. I have never been in such a high-energy learning environment as this course. The main things I learned at CSHL are that there is no single definition of proteomics; the future of proteomics involves extremely high technology equipment, which has a very fast rate of obsolescence; proteomics requires multidisciplinary collaboration and large amounts of money; trained proteomicists will become more common, but at this time they are very rare.
Specifically for chicken immunoproteomics we need to attract highly trained and competent scientists. Proteomics also needs to become accessible to scientists outside the MS world. It is critical that chicken immunoproteomics grant application and manuscript reviewers are comfortable with the size and scope of proteomes as well as proteomics techniques and technologies and the capabilities and limitations of these.
Finally, proteomics is simply an organized collection of platform technologies with a definite goal of defining and understanding proteomes. The biological questions remain fundamentally important. Proteomics merely provides a set of tools to use for solving these biological questions.
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